Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of alprenolol alone and in combination with hydralazine on plasma renin concentration has been studied in 25 patients with arterial hypertension. Alprenolol caused a significant fall in plasma renin concentration and in BP but the two falls were not intercorrelated. Addition of hydralazine to the treatment regimen produced a further reduction of BP. Changes in plasma renin concentration varied greatly during combination therapy. A modest, non-significant increase in plasma renin concentration was measured compared with the level after treatment with alprenolol. It is concluded that mechanisms other than suppression of plasma renin concentration are important for the reduction of BP during beta-adrenergic blockade and that the plasma renin concentration probably has no clinical significance with regard to forecasting the antihypertensive effect of alprenolol. Even though a significant correlation was found between the fall in plasma renin concentration and the fall in diastolic BP during combination therapy, it is uncertain whether changes in the renin-angiotensin system are of primary importance for BP regulation during this therapy.
 ...
PMID:Effect of alprenolol and hydralazine on plasma renin concentration in patients with arterial hypertension. 119 14

The clinical benefits and hemodynamic effects of continuous alprenolol infusion for control of hypertension in the acute stage of ruptured cerebral aneurysms were investigated. Twenty-five patients manifesting systemic hypertension (greater than 160/100 mmHg) were treated with alprenolol, a beta-adrenergic antagonist, phentolamine, an alpha-adrenergic antagonist, and trimethaphan camsilate, a ganglionic blocker, given intravenously. All drugs decreased the mean arterial blood pressure significantly. However, alprenolol decreased the heart rate and cardiac index while phentolamine increased them. Alprenolol also decreased arterial catecholamine and renin activity, but caused no change in central venous pressure, pulmonary capillary wedge pressure, pulmonary vascular resistance, and systemic vascular resistance. The results indicate the usefulness of continuous alprenolol infusion for the control of acute hypertension in hemorrhagic cerebrovascular disease. The mode of action of alprenolol is also discussed.
 ...
PMID:Continuous alprenolol infusion for control of hypertension in the acute stage of ruptured intracranial aneurysms. 172 Feb 17

Changes in arterial blood pressure were compared in young male SHR rats untreated or treated orally with a beta-blocker for 5 days out of 7 from the 5th to 9th week of life. Propranolol, acebutolol and practolol, at a daily dose of 50 mg/kg, prevented the occurrence of hypertension, not only during the 4 weeks of treatment, but also during 6,9 and 11 weeks respectively after cessation of treatment. Alprenolol and metoprolol (50 mg/kg/day) and atenolol (100 mg/kg/day) proved to be active only during the period of treatment, whereas oxprenolol (100 mg/kg/day) was totally inactive. Propranolol and acebutolol were, however, inactive under identical conditions with SHR of the same strain but bred in another laboratory. The physiological difference between the two groups of SHR was confirmed by the fact that the resistance of their erythrocytes to osmotic shock was different. This suggests that all the beta-blockers do not necessarily have the same preventive activity with respect to hypertension in the SHR and that two groups of SHR bred in two different places can be physiologically dissimilar even though they originate from the same strain.
 ...
PMID:Variability in the preventive action of the B-blockers on genetic hypertension in the rat. 612 Apr 97